Expression and characterization of human tissue kallikrein variants

被引:15
作者
Chan, H
Springman, EB
Clark, JM
机构
[1] Axys Pharmaceut Corp, Dept Biol Mol, S San Francisco, CA 94080 USA
[2] Axys Pharmaceut Corp, Dept Biochem & Enzymol, S San Francisco, CA 94080 USA
关键词
D O I
10.1006/prep.1997.0854
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Human tissue kallikrein is a serine protease implicated in the pathology of various inflammatory disorders. As one of the two principal enzymes that generate proinflammatory kinin peptides in vivo, tissue kallikrein represents an attractive target for therapeutic intervention in diseases such as asthma, pancreatitis, and rheumatoid arthritis. Three distinct human tissue kallikrein variants, differing in one or two amino acid substitutions, are predicted to exist based on genomic or cDNA nucleotide sequences derived from different tissues. The effects of these substitutions on the biochemical properties of tissue kallikrein are unknown but could, in principle, confer tissue-specific functions on the enzyme or affect the clinical utility of specific kallikrein inhibitors. All three variants, as well as a deglycosylated derivative, were expressed in high yield as recombinant proteins in Pichia pastoris. The recombinant kallikrein variants and natural urinary kallikrein all hydrolyzed synthetic peptides with similar specificity and efficiency and released kallidin from kininogen at comparable rates. Similarly, no significant differences were observed in the interactions between kallikrein variants and protein inhibitors such as SBTI, alpha(1)-PI, and aprotinin. We conclude that the known tissue kallikrein variants represent allelic variants and are not likely to have tissue-specific activity related to the amino acid substitutions. (C) 1998 Academic Press.
引用
收藏
页码:361 / 370
页数:10
相关论文
共 43 条
[1]   A BRADYKININ ANTAGONIST MODIFIES ALLERGEN-INDUCED MEDIATOR RELEASE AND LATE BRONCHIAL RESPONSES IN SHEEP [J].
ABRAHAM, WM ;
BURCH, RM ;
FARMER, SG ;
SIELCZAK, MW ;
AHMED, A ;
CORTES, A .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (04) :787-796
[2]   CLONING AND EXPRESSION OF HUMAN SALIVARY-GLAND KALLIKREIN IN ESCHERICHIA-COLI [J].
ANGERMANN, A ;
BERGMANN, C ;
APPELHANS, H .
BIOCHEMICAL JOURNAL, 1989, 262 (03) :787-793
[3]   PURIFICATION AND CHARACTERIZATION OF HUMAN SALIVARY-GLAND PROKALLIKREIN FROM RECOMBINANT BACULOVIRUS-INFECTED INSECT CELLS [J].
ANGERMANN, A ;
RAHN, HP ;
HEKTOR, T ;
FERTIG, G ;
KEMME, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 206 (01) :225-233
[4]   REDUCTION BY HOE-140, THE B-2 KININ RECEPTOR ANTAGONIST, OF ANTIGEN-INDUCED NASAL BLOCKAGE [J].
AUSTIN, CE ;
FOREMAN, JC ;
SCADDING, GK .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (04) :969-971
[5]   HUMAN-KIDNEY KALLIKREIN - CDNA CLONING AND SEQUENCE-ANALYSIS [J].
BAKER, AR ;
SHINE, J .
DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY, 1985, 4 (06) :445-450
[6]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[7]  
BRAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323
[8]   A BRADYKININ ANTAGONIST INHIBITS CARRAGEENAN EDEMA IN RATS [J].
BURCH, RM ;
DEHAAS, C .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1990, 342 (02) :189-193
[9]   DETERMINANTS OF THE UNUSUAL CLEAVAGE SPECIFICITY OF LYSYL-BRADYKININ-RELEASING KALLIKREINS [J].
CHAGAS, JR ;
PORTARO, FCV ;
HIRATA, IY ;
ALMEIDA, PC ;
JULIANO, MA ;
JULIANO, L ;
PRADO, ES .
BIOCHEMICAL JOURNAL, 1995, 306 :63-69
[10]  
CHASE T, 1970, METHOD ENZYMOL, V19, P20